SCHEMBL4676253

SCHEMBL4676253

O=C(O)C(O)=CC(=O)c1ccoc1Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
GAA P10253 2/20 0.39
POLB P06746 3/20 0.37
USP2 O75604 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
TP53 P04637 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
GFER P55789 1/20 0.36
TSHR P16473 1/20 0.36
HNF4A P41235 1/20 0.36
GPR52 Q9Y2T5 1/20 0.35
GPR55 Q9Y2T6 1/20 0.34
PTPN1 P18031 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
ESR1 P03372 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676250 1.00 CYP2C19 (0.40) CYP2C19CYP3A4CYP2C9GAAPOLB
SCHEMBL4672763 0.89 TP53 (0.47) CYP2C19CYP3A4CYP2C9GAAPOLB
SCHEMBL4672759 0.89 TP53 (0.47) CYP2C19CYP3A4CYP2C9GAAPOLB
SCHEMBL4672235 0.87 TP53 (0.36) CYP2C19CYP3A4CYP2C9POLBKMT2A
SCHEMBL4675011 0.87 TP53 (0.35) POLBKMT2AMEN1TP53ALDH1A1
SCHEMBL4675037 0.87 ITGB1 (0.35) CYP2C19CYP3A4CYP2C9POLBKMT2A
SCHEMBL4675032 0.87 ITGB1 (0.35) CYP2C19CYP3A4CYP2C9POLBKMT2A
SCHEMBL4672238 0.87 TP53 (0.36) CYP2C19CYP3A4CYP2C9POLBKMT2A
SCHEMBL4675005 0.87 TP53 (0.35) POLBKMT2AMEN1TP53ALDH1A1
SCHEMBL4670971 0.87 HCAR2 (0.39) GAAPOLBALDH1A1GPR52TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CYP2C19 53/4885CYP3A4 4/4885CYP2C9 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.